Designed Specifically for Research into
Addiction, Clinical Outcomes,
Pharmacogenetics, and Treatment Approaches
The BioRealm ACOPT array, previously available as Smokescreen, was originally developed with support from the United States National Institute on Drug Abuse (NIDA) and collaboration with leading scientists, BioRealm has assembled a list of genetic variants from cutting-edge research on smoking and addiction to develop the Smokescreen® Genotyping Array.
Designed specifically for researchers interested in the causes of addiction and its treatment.
More addiction-related content, nicotine-related content, and tobacco-related content than any other commercially available array.
Better genome-wide imputation coverage of common variants than most similarly-sized arrays.
We designed the array’s content to support a variety of research goals related to addiction, smoking cessation, drug response, and the consequences of smoking.
Paired with Smokescreen software, researchers can take advantage of BioRealm’s bioinformatics and statistical genetics expertise with integrated quality control and data analysis.
Study samples are sent to one of BioRealm's partner labs and quality-controlled genotype data is returned in a matter of weeks. Scientists benefit from an end-to-end genotyping solution.
Covers 98% of common genetic variation in 1000+ addiction genes
More than 296,000 markers, selected for African, East Asian, and European populations
More than 20,000 markers from expert nomination, knowledge-bases, candidate gene arrays, and the literature
More nicotine and tobacco-related contenT
- More than 11,000 markers in the nicotine acetylcholine receptor gene cluster, CHRNA5-CHRNA3-CHRNB4, and nicotine metabolizer regions, CYP2A6-CYP2B6
- More than 16,000 markers for related co-morbidities and diseases
Better genome-wide imputation coverage of common variants
- African (66%)
- East Asian (82%)
- European (91%)
For investigative and research use only. Not intended for clinical diagnostic use.